How Twist’s New Preclinical-Grade Plasmid DNA Preps Could Reshape the TWST Nucleic Acid Therapeutics Story

In early December 2025, Twist Bioscience launched research-grade Plasmid DNA Preps with animal origin-free and endotoxin-free options tailored to stringent preclinical study requirements. This move ...
GEN - Genetic Engineering and Biotechnology News

Beyond Vaccines: Scaling the Promise of RNA Therapeutics

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade ...
Transparency Market Research

Plasmid Purification Market

Plasmid Purification Market to reach USD 6.6 Bn by 2035 at 12.3% CAGR, Driven by rising gene therapy demand, mRNA vaccines, ...